Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.

Published in: Health technology assessment (Winchester, England) (2024)

; Vol. 28, No. 49. See the NIHR Funding and Awards website for further award information.

Keyphrases